All In MedTech

FDA Clearance Tracker · P230032-S003

AvertD™ and AvertD™ Buccal Sample Collection Kit

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 29, 2026

Approved

Time to decision

30 days

Received Dec 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P230032-S003
Device name
AvertD™ and AvertD™ Buccal Sample Collection Kit
Applicant location
Carlsbad, CA
Received
Dec 30, 2025
Decided
Jan 29, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P230032

Device type

Device class
Class III

Every decision under product code QZH

FDA's approval statement

As written in FDA's record.

Approval of changes to the clinical protocol for the post-approval study (PAS) for P230032.

Source documents

Other decisions for AutoGenomics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.